Everything below concerns triple agonist. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2026-03-10. Numbers and descriptions here follow the published literature rather than marketing material.
Development has progressed from single- and multiple-ascending-dose studies in healthy volunteers into larger randomized trials in adults with obesity, type 2 diabetes, and fatty liver disease. Early reports describe dose-dependent reductions in body weight and improvements in glycemic markers over treatment periods of several months. Whether the glucagon arm adds tolerability cost without added benefit is still debated. Long-term cardiovascular outcomes, effects after treatment stops, and performance in older or comorbid populations are open questions rather than settled findings. Approval status may change, so the current investigational label should be confirmed against regulatory sources.
Retatrutide is an investigational synthetic peptide developed under the code LY3437943, with a backbone derived from glucose-dependent insulinotropic polypeptide. Several non-proteinogenic residues, including alpha-aminoisobutyric acid, appear in that backbone, and a fatty diacid side chain attached through a linker extends circulation time. The molecule carries roughly thirty-nine amino acid units and a total mass near 4.7 kilodaltons. Administration is by subcutaneous injection once weekly. Published work uses both the name retatrutide and the code LY3437943.
Pharmacologically the compound activates three receptors: GLP-1, GIP, and glucagon. GLP-1 and GIP signaling contribute to glucose-dependent insulin release, delayed gastric emptying, and reduced appetite, while glucagon receptor activation is associated with increased energy expenditure and hepatic fat oxidation. The single-molecule design is intended to keep these activities in one peptide rather than combining separate agents. Relative activity at each receptor differs, and the balance between them is a central question in interpretation. The glucagon component is partly offset by incretin-mediated insulin secretion, an interaction that remains incompletely characterized.
开发进程从早期单次和多次给药研究推进至大规模后期试验。公开报告显示，参与者在体重和相关代谢指标上出现变化，但完整数据需经同行评审并接受独立复核。试验设计通常包括随机、双盲和对照设置，以区分药物效应与行为干预。监管提交和标签范围尚未确定；长期维持效果与心血管结局仍是开放问题。
与仅靶向单一受体的同类药物相比，瑞他鲁肽增加胰高血糖素受体成分，理论上可提高能量消耗并改变脂肪分布。临床中观察到的体重变化是否主要来自该额外机制，目前尚无定论。胃肠道反应是该类药物常见不良事件，试验中通过剂量递增和监测进行管理。停药后体重反弹、个体差异和长期耐受性仍需更多数据。
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide of about 39 residues | Backbone derived from a GIP sequence |
| Molecular mass | Approximately 4.7 kDa | Peptide chain plus fatty diacid moiety |
| Receptor targets | GLP-1, GIP, glucagon | Unimolecular triple agonist |
| Typical storage temperature | 2 to 8 degrees Celsius | Protect from light; avoid repeated freeze-thaw |
| Common analytical method | LC-MS/MS | Used for plasma quantification and purity checks |
Solid peptide is generally held as a lyophilised powder at low temperature to slow degradation, with desiccant to limit moisture uptake. Reconstituted solutions are less stable and are usually kept refrigerated and protected from light for short periods. Repeated freeze-thaw cycles are avoided because they encourage aggregation. Laboratory handling includes work in a fume hood or laminar flow cabinet to limit inhalation and contamination. Weighing and transfer steps are performed with antistatic tools to reduce static-driven loss of fine powder.
Characterising a peptide of this size relies on a combination of chromatographic and mass spectrometric techniques. Reversed-phase high-performance liquid chromatography separates the intact molecule from related impurities, while electrospray mass spectrometry confirms molecular mass and detects truncation or oxidation products. Peptide mapping after enzymatic digestion verifies the amino acid sequence and locates modified residues. Because the molecule carries a lipid chain, assays must also distinguish the correctly conjugated product from incompletely acylated species.
Human evidence remains limited to controlled studies. A phase 2 trial in adults with obesity reported large, dose-dependent reductions in body weight over 48 weeks, with gastrointestinal events as the most frequently recorded adverse effect. Phase 3 programs designated TRIUMPH, for obesity, and TRANSCEND, for type 2 diabetes, are intended to confirm efficacy and to characterize safety in larger populations. Related studies are examining conditions such as knee osteoarthritis in people with obesity and metabolic liver disease. Open questions include long-term tolerability, effects on lean mass, and what happens after treatment is stopped.
Retatrutide is an investigational synthetic peptide that acts on three receptor targets at once: glucose-dependent insulinotropic polypeptide, glucagon-like peptide-1, and glucagon. It is developed by Eli Lilly and appears in the literature and in trial registries under the code LY3437943. The molecule belongs to a class of engineered peptides designed to resist rapid breakdown and permit infrequent subcutaneous administration. No regulatory agency has approved it for clinical use, and all available human data come from controlled trials rather than from routine practice.
protein with a deep cleft for binding the RNA substrate. The first layer is composed of three alpha helices (residues 3–13, 24-34 and 50–60) from the N-terminal half of the protein. The second layer consist of three β-hairpins (residues 61–74, 79-104 and 105-124 from the C-terminal half) arranged in two β-sheets. The hairpins 61-74 and 105-124 form a four-stranded, antiparallel β-sheet that lies on helix 3 (residues 50–60). The longest β-hairpin 79-104 mates with a short β-strand (residues 42–45) to form a three-stranded, antiparallel β-sheet that lies on helix 2 (residues 24–34). RNase A has four disulfide bonds in its native state: Cys26-Cys84, Cys58-110, Cys40-95 and Cys65-72. The first two (26-84 and 58–110) are essential for conformational folding; each joins an alpha helix of the first layer to a beta sheet of the second layer, forming a small hydrophobic core in its vicinity. The latter two disulfide bonds (40-95 and 65–72) are less essential for folding; either one can be reduced (but not both) without affecting the native structure under physiological conditions. These disulfide bonds connect loop segments and are relatively exposed to solvent. The 65-72 disulfide bond has an extraordinarily high propensity to form, significantly more than would be expected from its loop entropy, both as a peptide and in the full-length protein. This suggests that the 61-74 β-hairpin has a high propensity to fold conformationally. RNase A is a basic protein (pI = 9.63); its many positive charges are consistent with its binding to RNA (a poly-anion).
== Correlation == It has been found that the F number linearly correlates with the log k' value (logarithm of the retention factor) in aqueous reversed-phase liquid chromatography. This relationship can be used to understand the significance of different aspects of molecular architecture on their separation using different stationary phases. This size analysis is complementary to the length-to-breadth (L/B) ratio, which classifies molecules according to their "rodlike" or "squarelike" shape.
Hadacidin, and hadacidin analogues, have anticancer activity and activity against adenylosuccinate synthetase. Hadacidin is the simplest known naturally occurring hydroxamic acid. The hydroxylamino group is frequently donated by a hydroxylamino acid such as 8-N-hydroxyornithine of the siderochromes. This compound, first isolated and characterized by Kaczka et al. in 1962, seemed well suited for a study of the route of hydroxamic acid biosynthesis. The hydroxamate bond may be considered to be a peptide bond with an oxygen atom on the amide nitrogen, but there is no a priori reason to decide whether the oxygen atom is introduced before or after the formation of the amide bond. In the latter case, formylglycine would be an intermediate in hadacidin biosynthesis. N-Hydroxylation of an amide bond was reported by Cramer et al. (1960), who found that N-hydroxy-2-acetylaminofluorene was formed in the intact rat upon administration of 2-acetylaminofluorene. Nevertheless, this finding cannot be considered direct proof of N-hydroxylation of an amide bond because, as the authors point out, the acetyl group is labile in their experiments, and hydroxylation of the amino group might have occurred. Glycine, formate, and the 2-carbon of serine were all found to be very quickly incorporated into hadacidin during its synthesis by Penicillium aurantioviolaceum.
==== General election ==== On July 25, 2000, Bush surprised some observers when he selected Dick Cheney – a former White House chief of staff, U.S. representative, and secretary of defense – to be his running mate. At the time, Cheney was serving as head of Bush's vice presidential search committee. Soon after at the 2000 Republican National Convention, Bush and Cheney were officially nominated by the Republican Party. Bush continued to campaign across the country and touted his record as Governor of Texas. During his campaign, Bush criticized his Democratic opponent, incumbent vice president Al Gore, over gun control and taxation. When the election returns were tallied on November 7, Bush had won 29 states, including Florida. The closeness of the Florida outcome led to a recount. The initial recount also went to Bush, but the outcome was tied up in lower courts for a month until eventually reaching the U.S. Supreme Court. On December 9, in the controversial Bush v. Gore ruling, the Court reversed a Florida Supreme Court decision that had ordered a third count, and stopped an ordered statewide hand recount based on the argument that the use of different standards among Florida's counties violated the Equal Protection Clause of the Fourteenth Amendment. The machine recount showed that Bush had won the Florida vote by a margin of 537 votes out of six million casts.
Sources: en.wikipedia.org
Body fluid loss is measured in two major ways–sensible and insensible. Sensible is defined as being able to be measured in some way; vomiting, urination and defecation are all considered to be sensible losses as they have the ability to be measured. An insensible loss example is breathing because while there are some fluid losses, it is not possible to measure the amount of them. With a condition like fever, it is possible to measure the amount of fluid losses from it with a formula that increases by 7% for each degree of above normal body temperature, so it would be classed as a sensible loss. A check of the pet's gums and skin can indicate dehydration; gums become tacky and dry and skin does not snap back quickly when pinched if dehydration is present. When the skin at the back is lifted, a dehydrated animal's does not fall back into place quickly. Serious dehydration (loss of 10–12% of body fluids) means the pulled up skin stays there and does not go back into place. At this point, the animal may go into shock; dehydration of 12% or more is an immediate medical emergency. Hypovolemic shock is a life-threatening medical condition in which the heart is unable to pump sufficient blood to the body, due to loss of fluids. Dehydration can change the way subcutaneous insulin is absorbed, so either hyperglycemia or hypoglycemia are possible; dehydration can also cause false negative or positive urine ketone test results. Hyperglycemia means more of a risk for dehydration.
=== EC 1.3.1 With NAD+ or NADP+ as acceptor === EC 1.3.1.1: dihydrouracil dehydrogenase (NAD+) EC 1.3.1.2: dihydropyrimidine dehydrogenase (NADP+) EC 1.3.1.3: Δ4-3-oxosteroid 5β-reductase EC 1.3.1.4: transferred to EC 1.3.1.22, 3-oxo-5α-steroid 4-dehydrogenase (NADP+) EC 1.3.1.5: cucurbitacin Δ23-reductase EC 1.3.1.6: fumarate reductase (NADH) EC 1.3.1.7: meso-tartrate dehydrogenase EC 1.3.1.8: acyl-CoA dehydrogenase (NADP+) EC 1.3.1.9: enoyl-[acyl-carrier-protein] reductase (NADH) EC 1.3.1.10: enoyl-[acyl-carrier-protein] reductase (NADPH, Si-specific) EC 1.3.1.11: 2-coumarate reductase EC 1.3.1.12: prephenate dehydrogenase EC 1.3.1.13: prephenate dehydrogenase (NADP+) EC 1.3.1.14: dihydroorotate dehydrogenase (NAD+) EC 1.3.1.15: dihydroorotate dehydrogenase (NADP+) EC 1.3.1.16: β-nitroacrylate reductase EC 1.3.1.17: 3-methyleneoxindole reductase EC 1.3.1.18: kynurenate-7,8-dihydrodiol dehydrogenase EC 1.3.1.19: cis-1,2-dihydrobenzene-1,2-diol dehydrogenase EC 1.3.1.20: trans-1,2-dihydrobenzene-1,2-diol dehydrogenase EC 1.3.1.21: 7-dehydrocholesterol reductase EC 1.3.1.22: 3-oxo-5α-steroid 4-dehydrogenase (NADP+) EC 1.3.1.23: Identical to EC 1.3.1.3, Δ4-3-oxosteroid 5β-reductase EC 1.3.1.24: biliverdin reductase EC 1.3.1.25: 1,6-dihydroxycyclohexa-2,4-diene-1-carboxylate dehydrogenase EC 1.3.1.26: Now EC 1.17.1.8, 4-hydroxy-tetrahydrodipicolinate reductase EC 1.3.1.27: 2-hexadecenal reductase EC 1.3.1.28: 2,3-dihydro-2,3-dihydroxybenzoate dehydrogenase EC 1.3.1.29: cis-1,2-dihydro-1,2-dihydroxynaphthalene dehydrogenase EC 1.3.1.30: transferred to EC 1.3.1.22, 3-oxo-5α-steroid 4-dehydrogenase (NADP+) EC 1.3.1.31: 2-enoate reductase EC 1.3.1.32: maleylacetate reductase EC 1.3.1.33: protochlorophyllide reductase EC 1.3.1.34: 2,4 Dienoyl-CoA reductase (NADPH) EC 1.3.1.35: Now EC 1.14.19.22, microsomal oleoyl-lipid 12-desaturase EC 1.3.1.36: geissoschizine dehydrogenase EC 1.3.1.37: cis-2-enoyl-CoA reductase (NADPH) EC 1.3.1.38: trans-2-enoyl-CoA reductase (NADPH) EC 1.3.1.39: trans-2-enoyl-CoA reductase (NADPH) EC 1.3.1.40: 2-hydroxy-6-oxo-6-phenylhexa-2,4-dienoate reductase EC 1.3.1.41: xanthommatin reductase EC 1.3.1.42: 12-oxophytodienoate reductase EC 1.3.1.43: arogenate dehydrogenase EC 1.3.1.44: trans-2-enoyl-CoA reductase (NAD+) EC 1.3.1.45: 2′-hydroxyisoflavone reductase EC 1.3.1.46: biochanin-A reductase EC 1.3.1.47: α-santonin 1,2-reductase EC 1.3.1.48: 13,14-dehydro-15-oxoprostaglandin 13-reductase EC 1.3.1.49: cis-3,4-dihydrophenanthrene-3,4-diol dehydrogenase EC 1.3.1.50: n Now EC 1.1.1.252 tetrahydroxynaphthalene reductase EC 1.3.1.51: 2′-hydroxydaidzein reductase EC 1.3.1.52: Now EC 1.3.8.5, 2-methyl-branched-chain-enoyl-CoA reductase EC 1.3.1.53: (3S,4R)-3,4-dihydroxycyclohexa-1,5-diene-1,4-dicarboxylate dehydrogenase EC 1.3.1.54: precorrin-6A reductase EC 1.3.1.55: identical to EC 1.3.1.25, 1,6-dihydroxycyclohexa-2,4-diene-1-carboxylate dehydrogenase EC 1.3.1.56: cis-2,3-dihydrobiphenyl-2,3-diol dehydrogenase EC 1.3.1.57: phloroglucinol reductase EC 1.3.1.58: 2,3-dihydroxy-2,3-dihydro-p-cumate dehydrogenase EC 1.3.1.59: There is no evidence that the enzyme exists EC 1.3.1.60: dibenzothiophene dihydrodiol dehydrogenase EC 1.3.1.61: identical to EC 1.3.1.53, (3S,4R)-3,4-dihydroxycyclohexa-1,5-diene-1,4-dicarboxylate dehydrogenase EC 1.3.1.62: pimeloyl-CoA dehydrogenase EC 1.3.1.63: Now EC 1.21.1.2, 2,4-dichlorobenzoyl-CoA reductase EC 1.3.1.64: phthalate 4,5-cis-dihydrodiol dehydrogenase EC 1.3.1.65: 5,6-dihydroxy-3-methyl-2-oxo-1,2,5,6-tetrahydroquinoline dehydrogenase EC 1.3.1.66: cis-dihydroethylcatechol dehydrogenase EC 1.3.1.67: cis-1,2-dihydroxy-4-methylcyclohexa-3,5-diene-1-carboxylate dehydrogenase EC 1.3.1.68: 1,2-dihydroxy-6-methylcyclohexa-3,5-dienecarboxylate dehydrogenase EC 1.3.1.69: zeatin reductase EC 1.3.1.70: Δ14-sterol reductase EC 1.3.1.71: Δ24(241)-sterol reductase EC 1.3.1.72: Δ24-sterol reductase EC 1.3.1.73: 1,2-dihydrovomilenine reductase EC 1.3.1.74: 2-alkenal reductase [NAD(P)+] EC 1.3.1.75: 3,8-divinyl protochlorophyllide a 8-vinyl-reductase (NADPH) EC 1.3.1.76: precorrin-2 dehydrogenase EC 1.3.1.77: anthocyanidin reductase [(2R,3R)-flavan-3-ol-forming] EC 1.3.1.78: arogenate dehydrogenase (NADP+) EC 1.3.1.79: arogenate dehydrogenase (NAD(P)+) EC 1.3.1.80: Now classified as EC 1.3.7.12, red chlorophyll catabolite reductase EC 1.3.1.81: (+)-pulegone reductase EC 1.3.1.82: (-)-isopiperitenone reductase EC 1.3.1.83: geranylgeranyl diphosphate reductase EC 1.3.1.84: acrylyl-CoA reductase (NADPH) EC 1.3.1.85: crotonyl-CoA carboxylase/reductase EC 1.3.1.86: crotonyl-CoA reductase EC 1.3.1.87: 3-(cis-5,6-dihydroxycyclohexa-1,3-dien-1-yl)propanoate dehydrogenase EC 1.3.1.88: tRNA-dihydrouridine16/17 synthase (NAD(P)+) EC 1.3.1.89: tRNA-dihydrouridine47 synthase (NAD(P)+) EC 1.3.1.90: tRNA-dihydrouridine20a/20b synthase (NAD(P)+) EC 1.3.1.91: tRNA-dihydrouridine20 synthase (NAD(P)+) EC 1.3.1.92: artemisinic aldehyde Δ11(13)-reductase EC 1.3.1.93: very-long-chain enoyl-CoA reductase EC 1.3.1.94: polyprenol reductase EC 1.3.1.95: acrylyl-CoA reductase (NADH) EC 1.3.1.96: Botryococcus squalene synthase EC 1.3.1.97: botryococcene synthase EC 1.3.1.98: Now known to be catalyzed by two different enzymes, EC 1.3.1.122, (S)-8-oxocitronellyl enol synthase, and EC 5.5.1.34, (+)-cis,trans-nepetalactol synthase EC 1.3.1.100: chanoclavine-I aldehyde reductase EC 1.3.1.101: 2,3-bis-O-geranylgeranyl-sn-glycerol 1-phosphate reductase [NAD(P)H] EC 1.3.1.102: 2-alkenal reductase (NADP+) EC 1.3.1.103: 2-haloacrylate reductase EC 1.3.1.104: enoyl-[acyl-carrier-protein] reductase (NADPH) EC 1.3.1.105: 2-methylene-furan-3-one reductase EC 1.3.1.106: cobalt-precorrin-6A reductase EC 1.3.1.107: sanguinarine reductase EC 1.3.1.108: caffeoyl-CoA reductase EC 1.3.1.109: butanoyl-CoA dehydrogenase complex (NAD+, ferredoxin) EC 1.3.1.110: lactate dehydrogenase (NAD+,ferredoxin) EC 1.3.1.111: geranylgeranyl-bacteriochlorophyllide a reductase EC 1.3.1.112: anthocyanidin reductase [(2S)-flavan-3-ol-forming] EC 1.3.1.113: (4-alkanoyl-5-oxo-2,5-dihydrofuran-3-yl)methyl phosphate reductase EC 1.3.1.114: 3-dehydro-bile acid Δ4,6-reductase EC 1.3.1.115: 3-oxocholoyl-CoA 4-desaturase EC 1.3.1.116: 7β-hydroxy-3-oxochol-24-oyl-CoA 4-desaturase EC 1.3.1.117: hydroxycinnamoyl-CoA reductase EC 1.3.1.118: meromycolic acid enoyl-[acyl-carrier-protein] reductase EC 1.3.1.119: chlorobenzene dihydrodiol dehydrogenase EC 1.3.1.120: cyclohexane-1-carbonyl-CoA reductase NADP+) EC 1.3.1.121: 4-amino-4-deoxyprephenate dehydrogenase EC 1.3.1.122: (S)-8-oxocitronellyl enol synthase EC 1.3.1.123: 8-oxogeranial reductase EC 1.3.1.124: 2,4-dienoyl-CoA reductase [(3E)-enoyl-CoA-producing]
=== Location and Position === The apical foramen is the principal opening at a tooth's root terminus, serving as the conduit between the root canal system and the periapical tissues. Its location is variable, as it frequently deviates from the anatomical apex—the root's geometric tip. Studies indicate that in a majority of cases, the foramen is positioned laterally, most commonly on the distal aspect. The average deviation is typically less than 1 millimeter, though greater distances are observed in specific teeth such as mandibular canines and molars. The foramen's morphology is often oval but can be circular or irregular. Its precise location and shape can be influenced by ethnic background, age, and physiological changes. In clinical endodontics, accurate identification of the apical foramen, rather than reliance on the radiographic apex alone, is essential for determining the correct working length and ensuring treatment success.
Their hypotheses were confirmed in the mid-1970s and 1980s by Erwin Neher and Bert Sakmann, who developed the technique of patch clamping to examine the conductance states of individual ion channels. In the 21st century, researchers are beginning to understand the structural basis for these conductance states and for the selectivity of channels for their species of ion, through the atomic-resolution crystal structures, fluorescence distance measurements and cryo-electron microscopy studies. Julius Bernstein was also the first to introduce the Nernst equation for resting potential across the membrane; this was generalized by David E. Goldman to the eponymous Goldman equation in 1943. The sodium–potassium pump was identified in 1957 and its properties gradually elucidated, culminating in the determination of its atomic-resolution structure by X-ray crystallography. The crystal structures of related ionic pumps have also been solved, giving a broader view of how these molecular machines work.
Sidibé Aminata Diallo – Malian Academic and politician. former Minister of Basic Education, Literacy, and the National Languages. Mali Diarra Mariam Flantié Diallo - Minister of Communications And Technology, Mali. Souleymane Sidibé (politician) - former Minister of Internal Security and Civil Protection, Foreign Affairs. Ousmane Sy - Politician. former Minister of Territorial Administration and Local Communities; Mali. Sy Kadiatou Sow– Politician and Women's Rights Activist, former governor of Bamako district, the first woman to hold the position in Mali, former minister of foreign affairs, Foreign Malians and African Integration and former Minister of Urban Planning and Habitat. Mali Sangaré Niamoto Ba- Politician, former Ministry of Industry, Investment and Commerce Djibril Sidibé - Malian football player (Born 1982) Djibril Sidibé - French football player of Malian descent (Born 1992) Inna Modja - Singer, songwriter and activist Mamadou Sidibé - Malian musician Moussa Diaby Moctar Ouane- diplomat and politician. Prime minister; former minister of foreign affairs; former ambassador to the United Nations.
Sources: en.wikipedia.org
As of the mid-2020s retatrutide remains investigational and is not an approved medicine in the United States or the European Union. It has been supplied mainly to participants in clinical trials. Labels and availability can change, so regulatory listings should be checked directly.
Dual agonists act at the GLP-1 and GIP receptors, whereas retatrutide adds glucagon receptor activity on the same peptide. This third activity is the main structural and pharmacological distinction discussed in the literature. Direct head-to-head comparisons remain limited.
Reports usually give the study code LY3437943 alongside the name, the dose in milligrams, and the week at which an endpoint was measured. Percent body-weight change is the most frequent headline measure. Units and populations vary, so comparisons across reports require care.
尚未。它仍处于临床研究阶段，任何监管批准都取决于正在进行的试验结果和提交审评。可公开获取的信息以试验注册和会议摘要为主。